Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Br J Pharmacol ; 164(2b): 607-16, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21542828

RESUMO

BACKGROUND AND PURPOSE: We investigated the influence of metoprolol on gap junction proteins connexin43 (Cx43) and connexin40 (Cx40) in atrial tissue from patients with/without atrial fibrillation (AF). EXPERIMENTAL APPROACH: Left atrial tissue samples from 160 patients with AF or sinus rhythm (SR) with or without metoprolol (mean daily dose: 65.2 ± 9.1 mg·day⁻¹) were analysed for Cx43 and Cx40 by Western blot and immunohistology. Transverse and longitudinal conduction velocities were determined by 64 multi-electrode mapping. KEY RESULTS: Both Cx43 and Cx40 expression were significantly increased in patients with AF versus SR. Cx43-expression in AF was significantly higher in patients receiving metoprolol, while Cx40 expression was unaffected by metoprolol treatment. In AF, the ratio of lateral/polar expression of Cx43 and Cx40 was enhanced due to increased expression at the sides of the cells (lateral) and a loss at the cell poles. This AF-induced increase in lateral/polar expression of Cx43, but not of Cx40, was significantly antagonized by metoprolol treatment. Functionally, in AF patients, transverse conduction velocity in atrial samples was significantly enhanced and this change was also significantly antagonized by metoprolol. CONCLUSIONS AND IMPLICATIONS: AF induced enhanced lateral expression of Cx43 and Cx40 together with enhanced transverse conduction velocity in left atrial tissue. Alterations in localization of Cx43 and conduction changes were both antagonized by metoprolol, showing that pharmacological modulation of gap junction remodelling seems, in principle, possible. This finding may open new approaches to the development of anti-arrythmic drugs.


Assuntos
Fibrilação Atrial/tratamento farmacológico , Fibrilação Atrial/patologia , Junções Comunicantes/efeitos dos fármacos , Junções Comunicantes/patologia , Metoprolol/farmacologia , Antagonistas de Receptores Adrenérgicos beta 1/farmacologia , Fibrilação Atrial/genética , Fibrilação Atrial/metabolismo , Doença Crônica , Conexina 43/antagonistas & inibidores , Conexina 43/genética , Conexina 43/metabolismo , Conexinas/antagonistas & inibidores , Conexinas/genética , Conexinas/metabolismo , Feminino , Junções Comunicantes/genética , Junções Comunicantes/metabolismo , Átrios do Coração/efeitos dos fármacos , Átrios do Coração/metabolismo , Átrios do Coração/patologia , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Proteína alfa-5 de Junções Comunicantes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA